Brainstorm Cell Therapeutics Inc. (BCLI)
Oxford Ledge is still expanding full research coverage of BCLI. A delayed quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Brainstorm develops cell therapies derived from patients' own bone marrow cells for treating neurodegenerative diseases, with NurOwn in late-stage development for ALS.
Source: 10-K (2025-12-31) · AI-generated analysis. Not investment advice. May contain errors.
SEC filings
- 8-K Departure/election of directors or officers; Regulation FD disclosure; Financial statements and exhibits 2026-05-28
- S-1 IPO / securities registration statement 2026-05-21
- 8-K Results of operations / financial condition; Financial statements and exhibits 2026-05-15
- 10-Q Quarterly financial report (unaudited) 2026-05-15
- 10-K Annual financial report with audited statements 2026-03-31
Source: SEC EDGAR.
Annual results
5 years of annual figures for BCLI, as filed with the SEC. Figures are as reported and are not restated or adjusted.
| Fiscal year | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| 2025 | — | -$10.3M | -$1.11 |
| 2024 | — | -$11.6M | -$2.31 |
| 2023 | — | -$17.2M | -$6.00 |
| 2022 | — | -$24.3M | -$0.66 |
| 2021 | — | -$24.5M | -$0.68 |
Source: SEC EDGAR (XBRL company facts). Full statements and ratios in the terminal.
Insider activity
5 recent insider (SEC Form 4) filings on record for BCLI. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open BCLI in the Oxford Ledge terminal — delayed quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.